Ethiopia sits at elevations ranging from 125 meters below sea level in the Danakil Depression to 4,550 meters at Ras Dashen in the Simien Mountains. The Ethiopian Highlands, where Addis Ababa stands at 2,355 meters, create altitude conditions that affect physiological adaptation for most visitors. Travelers arriving in Addis Ababa from sea level locations commonly experience mild symptoms of acute mountain sickness within the first 24 to 48 hours, including headache, fatigue, and disrupted sleep. The body requires approximately three to five days to increase red blood cell production and adjust respiratory patterns to reduced oxygen availability at this elevation. Visitors planning to trek in the Simien Mountains above 3,000 meters or visit Lalibela at 2,630 meters should account for additional acclimatization time. The standard medical recommendation for altitude adaptation involves ascending no more than 300 to 500 meters per day when sleeping above 3,000 meters, though this guidance applies primarily to multi-day treks rather than direct flights into highland cities.
Yellow fever vaccination carries mandatory status for all travelers entering Ethiopia if arriving from countries with yellow fever transmission risk, defined by the World Health Organization list that includes 47 nations across Africa and South America. Ethiopian border officials require presentation of the International Certificate of Vaccination or Prophylaxis showing yellow fever immunization administered at least ten days before entry. This requirement applies regardless of transit duration in affected countries. Airlines enforce this requirement at departure points. The yellow fever vaccine provides protection for life according to WHO guidance updated in 2016, though some countries still reference the previous ten-year validity period on certificates. Travelers should verify that their vaccination record shows administration of an approved vaccine strain and bears the stamp and signature of an authorized vaccination center.
Malaria transmission occurs in Ethiopian regions below 2,000 meters elevation, affecting approximately 75 percent of the country's land area where roughly 68 percent of the population lives. The Ethiopian Highlands, including Addis Ababa, Gondar, Lalibela, and the Simien Mountains, remain above the transmission threshold. The Danakil Depression, Awash National Park, Gambela, the Lower Omo Valley, and Mago National Park all fall within active transmission zones. Plasmodium falciparum accounts for 60 to 70 percent of malaria cases in Ethiopia, with Plasmodium vivax comprising most remaining infections. Antimalarial prophylaxis recommendations vary by specific itinerary rather than applying uniformly to Ethiopia travel. Atovaquone-proguanil, doxycycline, and mefloquine represent the three primary chemoprophylaxis options, each with different dosing schedules, contraindications, and side effect profiles. Travelers visiting only highland destinations above 2,000 meters typically receive medical guidance that antimalarial medication is unnecessary, while those including lowland areas in their itinerary receive opposite guidance. The decision requires consultation with a physician familiar with current resistance patterns, individual health history, and specific geographic routing.
Hepatitis A transmission occurs through contaminated food and water across Ethiopia, with no geographic variation in risk level. The hepatitis A vaccine requires two doses administered six to twelve months apart for long-term protection, though a single dose provides adequate immunity for trips occurring within the first six months after initial vaccination. Nearly all travelers to Ethiopia receive medical recommendation for hepatitis A vaccination regardless of itinerary, accommodation standard, or trip duration. Hepatitis B spreads through blood and bodily fluid contact, with prevalence in Ethiopia estimated at 4.7 to 7.4 percent of the population based on studies conducted between 2011 and 2016 in different regions. Vaccination recommendations for hepatitis B depend on anticipated activities, trip duration, and individual risk factors including planned medical procedures, adventure activities with injury potential, or stays exceeding one month. The hepatitis B vaccine series requires three doses over a six-month period for standard scheduling, though accelerated schedules exist for travelers departing sooner.
Typhoid fever occurs throughout Ethiopia, transmitted through food and water contaminated with Salmonella typhi bacteria. Two vaccine types exist: an injectable polysaccharide vaccine providing protection for two years, and an oral live attenuated vaccine given in four capsules on alternate days providing protection for five years. The oral vaccine requires completion at least one week before potential exposure and carries restrictions against use by immunocompromised individuals or those taking antibiotics during the vaccination period. Typhoid vaccination receives medical recommendation for most Ethiopia travelers, particularly those visiting smaller cities, rural areas, or staying with local families where food preparation standards may differ from international hotel environments. Studies of typhoid incidence among travelers to East Africa indicate attack rates of approximately 4 to 10 cases per 100,000 travelers for trips under one month, increasing substantially for longer stays and different travel styles.
Rabies exists throughout Ethiopia in dogs, bats, and other mammals. The country reports several hundred suspected rabies exposures annually among travelers, though exact numbers remain incompletely documented. Pre-exposure rabies vaccination consists of three doses administered over 21 to 28 days and does not eliminate the need for post-exposure treatment but reduces the number of required doses from four or five to two and eliminates the need for rabies immunoglobulin, which remains unavailable in much of Ethiopia. Travelers planning extended stays in rural areas, participating in activities with animal contact, or visiting areas more than 24 hours from medical facilities capable of providing post-exposure prophylaxis receive medical recommendation for pre-exposure vaccination. Urban visitors on short trips with ready access to medical facilities in Addis Ababa typically receive different guidance. Post-exposure treatment must begin within hours to days of a potential rabies exposure, defined as a bite or scratch from any mammal, or contact between an animal's saliva and broken skin or mucous membranes. The difficulty of obtaining appropriate post-exposure treatment outside major Ethiopian cities weighs into pre-trip vaccination decisions.
Meningococcal meningitis occurs in Ethiopia, which sits within the African meningitis belt extending from Senegal to Ethiopia across the Sahel and sub-Sahel regions. Seasonal patterns show increased transmission during the dry season from December to June, with peak incidence typically occurring from February through April. Ethiopia experienced meningitis outbreaks in multiple regions during 2012, 2016, and 2019, with case numbers varying by year and location. The quadrivalent meningococcal conjugate vaccine covering serogroups A, C, W, and Y provides protection against the strains most commonly causing disease in this region. Meningococcal serogroup A historically caused the majority of epidemic disease in the meningitis belt, though serogroups W and C have increased in relative frequency following introduction of the MenAfriVac vaccine in 2011. Vaccination recommendations apply particularly to travelers visiting during dry season months, those with extended rural stays, or individuals with increased exposure risk through crowded conditions or close population contact.
Polio vaccination status requires verification for Ethiopia travel following the country's documentation of circulating vaccine-derived poliovirus type 2 cases in 2019 and 2020. Ethiopia conducts routine polio immunization campaigns, and wild poliovirus has not been detected since 2014, though the vaccine-derived strains occasionally emerge in populations with immunity gaps. Adults who completed the standard childhood polio vaccination series require a single adult booster dose if their last dose occurred more than ten years before Ethiopia travel. This recommendation follows guidance from the US Centers for Disease Control and Prevention updated in 2019 based on Ethiopia's classification status. Documentation of the booster dose may be requested at borders, though enforcement varies.
Routine vaccinations including measles-mumps-rubella, diphtheria-tetanus-pertussis, and varicella receive verification recommendations before Ethiopia travel. Measles circulation continues in Ethiopia with periodic outbreaks, most recently documented in multiple regions during 2018 and 2019 with several thousand reported cases. Adults born after 1957 should verify receipt of two measles-containing vaccine doses or laboratory evidence of immunity. Tetanus boosters require administration every ten years, with combination Td or Tdap vaccines providing simultaneous protection against diphtheria and pertussis. These vaccines are not Ethiopia-specific but represent baseline immunization status verification relevant for all international travel.